Cargando…

Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges

BACKGROUND: Lipodystrophy (LD; non-human immunodeficiency virus [HIV]-associated) syndromes are a rare body of disorders for which true prevalence is unknown. Prevalence estimates of rare diseases are important to increase awareness and financial resources. Current qualitative and quantitative estim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiquette, Elaine, Oral, Elif A, Garg, Abhimanyu, Araújo-Vilar, David, Dhankhar, Praveen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604558/ https://www.ncbi.nlm.nih.gov/pubmed/29066925 http://dx.doi.org/10.2147/DMSO.S130810

Ejemplares similares

Novel Heterozygous LMNA Variants Causing Familial Partial Lipodystrophy, Dunnigan Variety
por: Wadhwa, Akhilesh, et al.
Publicado: (2021)

The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline
por: Brown, Rebecca J., et al.
Publicado: (2016)

Untangling the Heterogeneity of Acquired Generalized Lipodystrophy
por: Cavdar, Umit, et al.
Publicado: (2021)

2287 ECG and echo characteristics in familial partial lipodystrophy: The impact of Lamin A variants
por: Eldin, Abdelwahab J., et al.
Publicado: (2018)

FRI054 Partial Lipodystrophy As A Manifestation Of Autoimmune Polyglandular Syndrome 1
por: Agarwal, Shubham, et al.
Publicado: (2023)

Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis
por: Cook, Keziah, et al.
Publicado: (2021)

SUN-556 Cardiac Phenotype in Familial Partial Lipodystrophy
por: Eldin, Abdelwahab Jalal, et al.
Publicado: (2020)

Phenotypic Differences Among Familial Partial Lipodystrophy Due to LMNA or PPARG Variants
por: Vasandani, Chandna, et al.
Publicado: (2022)

Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program
por: Ajluni, Nevin, et al.
Publicado: (2016)

MON-695 Multiple Recurrent Lipomatoses with Thiazolidinedione Therapy in Familial Partial Lipodystrophy, Dunnigan Variety (FPLD2)
por: Patni, Nivedita, et al.
Publicado: (2020)

Current Diagnosis, Treatment and Clinical Challenges in the Management of Lipodystrophy Syndromes in Children and Young People
por: Özen, Samim, et al.
Publicado: (2020)

PSUN138 Demonstration of Progressive Beta-Cell Failure in Familial Partial Lipodystrophy
por: De Freitas, Maria Foss, et al.
Publicado: (2022)

Iron parameters in patients with partial lipodystrophy and impact of exogenous leptin therapy
por: Akinci, Efe Y, et al.
Publicado: (2021)

Abnormal Non Esterified Fatty Acid Suppression After a Mixed Meal Test in Patients With Partial Lipodystrophy
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2021)

SUN-607 Iron Parameters in Patients with Partial Lipodystrophy and Impact of Metreleptin Therapy
por: Boutros, Sabine, et al.
Publicado: (2020)

ECLip-the European consortium on lipodystrophies: an update
por: Araújo-Vilar, David
Publicado: (2015)

An Uncommon Association of Familial Partial Lipodystrophy, Dilated Cardiomyopathy, and Conduction System Disease
por: Panikkath, Ragesh, et al.
Publicado: (2016)

OR17-02 Changes in Hepatokines and Apolipoproteins Are Associated with Metabolic Response to Metreleptin in Partial Lipodystrophy
por: Akinci, Baris, et al.
Publicado: (2020)

SUN-LB111 Comparison of Phenotype and Metabolic Abnormalities Among Familial Partial Lipodystrophy Due to LMNA or PPARG Variants
por: Vasandani, Chandna, et al.
Publicado: (2020)

Natural history and comorbidities of generalised and partial lipodystrophy syndromes in Spain
por: Fernández-Pombo, Antía, et al.
Publicado: (2023)

MON-155 A Patient with Acquired Generalized Lipodystrophy (AGL, Lawrence Syndrome) in Association with CTLA-4 Haploinsufficiency
por: Ozer, Muhammet, et al.
Publicado: (2019)

SAT-622 Heterogeneity of Familial Partial Lipodystrophy Type 2 from a Genotype-Phenotype Perspective
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2020)

Diagnostic Challenge in PLIN1-Associated Familial Partial Lipodystrophy
por: Jéru, Isabelle, et al.
Publicado: (2019)

Inhibition of Angiopoietin-Like 3 (ANGPTL3) Reduces Adipose Tissue Insulin Resistance in Patients With Familial Partial Lipodystrophy
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2021)

Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin
por: Esfandiari, Nazanene H., et al.
Publicado: (2019)

Potential association of LMNA-associated generalized lipodystrophy with juvenile dermatomyositis
por: Sahinoz, Melis, et al.
Publicado: (2018)

SUN-135 Dual Energy X-Ray Absorptiometry (DEXA) as a Diagnostic Tool for Familial Partial Lipodystrophy, Dunnigan Variety (FPLD2)
por: Vasandani, Chandna, et al.
Publicado: (2019)

Autoantibodies Against Perilipin 1 as a Cause of Acquired Generalized Lipodystrophy
por: Corvillo, Fernando, et al.
Publicado: (2018)

Body Composition And Bone Mineral Differences According to Lamin A (LMNA) Genotype in Familial Partial Lipodystrophy Type 2
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2021)

SAT-087 Familial Generalized Lipodystrophy in Two Siblings Due to Homozygous p.Arg545His LMNA Mutation
por: Patni, Nivedita, et al.
Publicado: (2019)

OR33-02 The Treatment of Partial Lipodystrophy in the Setting of Neutralizing Antibody Against Metreleptin with Leptin Receptor Agonist REGN4461
por: Akinci, Baris, et al.
Publicado: (2020)

Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review
por: Fernandez-Pombo, Antia, et al.
Publicado: (2023)

SAT-617 Potential Utility of the Mixed Meal Test for Differential Diagnosis of Partial Lipodystrophy from Common Type 2 Diabetes and Truncal Obesity
por: Guraya, Armaan, et al.
Publicado: (2020)

Type 2 Diabetes With Partial Lipodystrophy of the Limbs: A new lipodystrophy phenotype
por: Strickland, Leah R., et al.
Publicado: (2013)

Diagnosis and treatment of lipodystrophy: a step-by-step approach
por: Araújo-Vilar, D., et al.
Publicado: (2018)

FRI058 Treatment With Mibavademab, A Novel Leptin Receptor Agonist, Is Associated With Improvement In Metabolic Parameters In Individuals With Generalized Lipodystrophy
por: Olenchock, Ben, et al.
Publicado: (2023)

FRI059 Long-term Follow-up On Partial Lipodystrophy Treated With Leptin Receptor Agonist Mibavademab(REGN4461)
por: Foss de Freitas, Maria Cristina, et al.
Publicado: (2023)

FRI057 Drug Concentrations And Dosing Considerations For Mibavademab, A Novel Leptin Receptor Agonist, In Individuals With Generalized Lipodystrophy
por: Mendell, Jeanne, et al.
Publicado: (2023)

Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study
por: Foss-Freitas, Maria C., et al.
Publicado: (2021)

Complement Factor D (adipsin) Levels Are Elevated in Acquired Partial Lipodystrophy (Barraquer–Simons syndrome)
por: Corvillo, Fernando, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ss1hhmr8mho794glqlrkugg2or